{"id":"W2602586354","doi":"10.1021/acsami.6b15987","title":"A New Spin on Antibody–Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells","year":2017,"lang":"en","type":"article","venue":"ACS Applied Materials & Interfaces","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute","keywords":"Trastuzumab; Fulvestrant; Materials science; Drug; Conjugate; Antibody-drug conjugate; Colloid; Nanotechnology; Combinatorial chemistry; Pharmacology; Antibody; Cancer; Monoclonal antibody; Chemical engineering; Medicine; Breast cancer; Tamoxifen; Immunology; Internal medicine; Chemistry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008343338,0.0006587117,0.001189265,0.0002649204,0.000480823,0.0009028893,0.00102702,0.0002150547,0.002505301],"category_scores_gemma":[0.0001044513,0.0005532765,0.00007164435,0.0001369791,0.0005128516,0.0002125306,0.0003554918,0.0004786352,0.001381645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002170988,"about_ca_system_score_gemma":0.0004568445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002833791,"about_ca_topic_score_gemma":0.0001009813,"domain_scores_codex":[0.996197,0.0001214919,0.0008116732,0.00101584,0.0008528769,0.001001071],"domain_scores_gemma":[0.9974616,0.0001831866,0.0005163222,0.001248959,0.0001635905,0.0004263227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002179849,0.0002337084,0.0001055087,0.0003503173,0.000242684,0.0001405453,0.00136398,0.00001645209,0.9690196,0.0003574631,0.02440033,0.001589549],"study_design_scores_gemma":[0.002523042,0.0006291223,0.0008996756,0.001287231,0.0001027011,0.00002846384,0.0005815531,0.000001804324,0.9891327,0.0006660824,0.003629764,0.0005178422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830279,0.0004130633,0.0000227797,0.002748471,0.001197219,0.001988559,0.0004370894,0.0001734324,0.009991514],"genre_scores_gemma":[0.9918261,0.0008473859,0.001079431,0.000505748,0.0007988059,0.0001433638,0.0001125672,0.0001439542,0.004542715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02077057,"threshold_uncertainty_score":0.9996918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0177802712335333,"score_gpt":0.3351322059789082,"score_spread":0.3173519347453749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}